Who should avoid self-directed recovery peptides
Andraos, J., Muhar, H
Outcomes Primary outcome measures were selected based on available vital and lab measurements that would capture the intended impact of GLP-1s especially for diabetic or obese patients, as at the time of this study, GLP-1 use had primarily been approved as therapy to improve glycemic control and support weight loss
The Danish company hasn't disclosed Wegovy's price but said it will be similar to the price of Saxenda, an 11-year-old weight loss drug injected daily that now typically costs more than $1,300 per month without insurance
Finally, with typically older, multi-morbid, obese patients the primary target segment for muscle-preserving therapies, long-term safety and tolerability data, including in polypharmacy situations, are a key prerequisite for their wider adoption, to address lingering concerns about some of the mechanisms of action being explored
These phrases can easily be mitigated in later stages and offer a great foundation for stage 1 GLPs
